Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus MYCELEX 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus MYCELEX 7 COMBINATION PACK.
AMPHOTEC vs MYCELEX-7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible.
Category C
Category C
Antifungal
Antifungal